---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-078549"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T05:06:05.726859+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oruka raises $200M via PIPE; accelerates ORKA-001/002 clinical timelines

## Summary
- Gross proceeds of ~$200M from sale of common stock, preferred stock, and pre-funded warrants at $23.00 per common share.
- Cash runway extended through 2027; closing expected September 13, 2024.
- First-in-human dosing of ORKA-001 (IL-23p19 mAb) now expected Q1 2025; ORKA-002 (IL-17A/F mAb) expected Q3 2025.
- Preclinical data show ORKA-001 half-life >30 days in NHPs; data to be presented at EADV September 25-28.
- Pro forma shares outstanding expected to be ~55.1 million including all conversions and warrants.

## SEC filing metadata
- accession: 0001213900-24-078549
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024078549/0001213900-24-078549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea0214439-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-078549
- JSON: https://secwatch.observer/filing/0001213900-24-078549.json
- Plain text: https://secwatch.observer/filing/0001213900-24-078549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.